Nancy Dumont
Overview
Explore the profile of Nancy Dumont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chutake Y, Mayo M, Dumont N, Filiatrault J, Breitkopf S, Cho P, et al.
Mol Cancer Ther
. 2024 Dec;
PMID: 39648478
Murine double minute 2 (MDM2) is an E3 ligase that inhibits the tumor suppressor protein p53. Clinical trials employing small-molecule MDM2/p53 interaction inhibitors (SMIs) have demonstrated limited activity, underscoring an...
2.
Jiang W, Shaw S, Rush J, Dumont N, Kim J, Singh R, et al.
bioRxiv
. 2024 Jun;
PMID: 38826457
Protein phosphatase, Mg/Mn dependent 1D (PPM1D), is a serine/threonine phosphatase that is recurrently activated in cancer, regulates the DNA damage response (DDR), and suppresses the activation of p53. Consistent with...
3.
Cervia L, Shibue T, Borah A, Gaeta B, He L, Leung L, et al.
Cancer Discov
. 2022 Dec;
13(3):766-795.
PMID: 36576405
Significance: We describe the identification of a heretofore unrecognized ubiquitin ligase complex that prevents the aberrant activation of the ISR in a subset of cancer cells. This provides a novel...
4.
Bondeson D, Paolella B, Asfaw A, Rothberg M, Skipper T, Langan C, et al.
Nat Cancer
. 2022 Apr;
3(6):681-695.
PMID: 35437317
Despite advances in precision medicine, the clinical prospects for patients with ovarian and uterine cancers have not substantially improved. Here, we analyzed genome-scale CRISPR-Cas9 loss-of-function screens across 851 human cancer...
5.
Neggers J, Paolella B, Asfaw A, Rothberg M, Skipper T, Yang A, et al.
Cell Rep
. 2021 Jul;
36(2):109367.
PMID: 34260938
No abstract available.
6.
Malone C, Dharia N, Kugener G, Forman A, Rothberg M, Abdusamad M, et al.
Cancer Discov
. 2021 Apr;
11(9):2282-2299.
PMID: 33883167
Cancer dependency maps, which use CRISPR/Cas9 depletion screens to profile the landscape of genetic dependencies in hundreds of cancer cell lines, have identified context-specific dependencies that could be therapeutically exploited....
7.
Neggers J, Paolella B, Asfaw A, Rothberg M, Skipper T, Yang A, et al.
Cell Rep
. 2020 Dec;
33(11):108493.
PMID: 33326793
Few therapies target the loss of tumor suppressor genes in cancer. We examine CRISPR-SpCas9 and RNA-interference loss-of-function screens to identify new therapeutic targets associated with genomic loss of tumor suppressor...
8.
Corsello S, Nagari R, Spangler R, Rossen J, Kocak M, Bryan J, et al.
Nat Cancer
. 2020 Jul;
1(2):235-248.
PMID: 32613204
Anti-cancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs...
9.
Sulahian R, Kwon J, Walsh K, Pailler E, Bosse T, Thaker M, et al.
Cell Rep
. 2019 Oct;
29(1):118-134.e8.
PMID: 31577942
The mitogen-activated protein kinase (MAPK) pathway is a critical effector of oncogenic RAS signaling, and MAPK pathway inhibition may be an effective combination treatment strategy. We performed genome-scale loss-of-function CRISPR-Cas9...
10.
Chan E, Shibue T, McFarland J, Gaeta B, Ghandi M, Dumont N, et al.
Nature
. 2019 Apr;
568(7753):551-556.
PMID: 30971823
Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer...